Determinant of 30-Day Mortality of Pulmonary Legionellosis: Do Coinfections Matter?
- PMID: 39319087
- PMCID: PMC11420677
- DOI: 10.1093/ofid/ofae529
Determinant of 30-Day Mortality of Pulmonary Legionellosis: Do Coinfections Matter?
Abstract
We retrospectively reviewed 64 cases of cancer with pulmonary legionellosis (Legionella pneumophila in 73%). Nearly all patients received Legionella-active antibiotics, yet 30-day mortality was 23%. Independent predictors of 30-day mortality were hyponatremia, bilateral lung involvement, and Sequential Organ Failure Assessment score ≥5. Lung coinfections were common (31%) but did not significantly increase mortality.
Keywords: Legionella; cancer; coinfections; mortality outcomes; pneumonia.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Conflict of interest statement
Potential conflicts of interest. D. P. K. reports honoraria and research support from Gilead Sciences and Astellas Pharma. He also received consultant fees from Astellas Pharma, Merck, and Gilead Sciences and is a member of the Data Review Committee for Cidara Therapeutics, AbbVie, Scynexis, and the Mycoses Study Group. All other authors report no potential conflicts.
Figures
References
-
- Jacobson Kalen L, Miceli Marisa H, Tarrand Jeffrey J, Kontoyiannis Dimitrios P. Legionella pneumonia in cancer patients. Medicine (Baltimore) 2008; 87:152–9. - PubMed
-
- Mikulska M, Tridello G, Hoek J, et al. Legionellosis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2021; 56:2555–66. - PubMed
-
- Sivagnanam S, Podczervinski S, Butler-Wu SM, et al. Legionnaires’ disease in transplant recipients: a 15-year retrospective study in a tertiary referral center. Transpl Infect Dis 2017; 19:e12745. - PubMed
-
- Sivagnanam S, Pergam Steven A. Legionellosis in transplantation. Curr Infect Dis Rep 2016; 18:9. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
